Mainz Biomed (MYNZ) CEO Issues Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/19/2026
- S&P 500, Nasdaq futures rise as AI stocks rebound ahead of key earnings
- U.S. economy is "booming," JPMorgan’s Dimon says
- Oil slips from 5-month high as Trump's Russia sanctions waiver may bring more supplies
- Prepare to buy the dip as U.S. stock selloff nears its end: Morgan Stanley
- Goldman warns high investor conviction could amplify volatility as sentiment shift
- Brazil's Bolsonaro, Lula spar in first debate as personal attacks fly
- Microsoft pulls out of UK data center deal with Nscale, Telegraph reports
- Lithuanians forced to take shelter after suspected drone enters airspace
- Oil slips from 5-month high as Trump's Russia sanctions waiver may bring more supplies
- Iran urges US to accept proposal to reopen Strait of Hormuz
Mainz Biomed Publishes CEO Statement; CEO Guido Baechler Eyes Major Growth and U.S. FDA Trials in 2025
October 1, 2024 8:01 AM EDTBERKELEY, Calif. and MAINZ, Germany, Oct. 01, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ: MYNZ) (Mainz Biomed or the Company), a molecular genetics diagnostic company specializing in the early detection of cancer, today released a statement to shareholders highlighting its strategic plans for maximizing shareholder value, clinical developments, and its upcoming FDA trial anticipated for 2025, which aims to pave the way for entry into the U.S. market. Management... More



